Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Net Cash Flow (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Net Cash Flow for 11 consecutive years, with -$18.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 177.74% to -$18.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$87.4 million, a 164.3% decrease, with the full-year FY2025 number at -$87.4 million, down 164.3% from a year prior.
  • Net Cash Flow was -$18.3 million for Q4 2025 at Cartesian Therapeutics, down from -$16.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $132.0 million in Q3 2024 to a low of -$34.0 million in Q3 2023.
  • A 5-year average of -$658900.0 and a median of -$8.8 million in 2021 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 7416.87% in 2022; the steepest drop was 992.78% in 2022.
  • Cartesian Therapeutics' Net Cash Flow stood at -$582000.0 in 2021, then plummeted by 992.78% to -$6.4 million in 2022, then surged by 57.42% to -$2.7 million in 2023, then tumbled by 142.73% to -$6.6 million in 2024, then tumbled by 177.74% to -$18.3 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Net Cash Flow are -$18.3 million (Q4 2025), -$16.9 million (Q3 2025), and -$20.1 million (Q2 2025).